BridgeLine Translational
Strategy work for the years before the clinic
Competitive intelligence, preclinical strategy, portfolio choices, and the materials investors and partners ask to see. Built by an operator who has designed IND-enabling programs and sat on the other side of the table during diligence.
Services
What we do
Four services. Each one scoped to what your program actually needs.
Competitive Intelligence
Competitive landscape analysis, competitor precedent review, and positioning. Know your space, what your competitors have done, and what their development choices mean for your program.
Learn morePreclinical Strategy
A study-by-study plan from lead candidate to IND. Model selection, endpoint choices, go/no-go gates, timelines, and budgets in one integrated roadmap.
Learn morePortfolio Strategy
Prioritize across programs and indications. Evaluate each against unmet need, competitive landscape, commercial viability, and development cost, then concentrate resources where they matter.
Learn moreInvestor & Partner Readiness
Organize the data, sharpen the narrative, and rehearse for investor and partner conversations. Structured data room, clear story, and answers ready for the questions that come up.
Learn moreHow It Works
How a project starts
A call to understand the program, a scoped engagement, and ongoing support if it makes sense.
Intro Call
A short call to share your program and the decisions in front of you. BridgeLine recommends the right starting point.
Engagement
One of the four services, scoped to your situation. Typically 2-4 weeks. Every deliverable is built for board, investor, and partner conversations.
Continued Support
Ongoing advisory support available for competitive monitoring, decision review, and strategic guidance as your program advances.
Built by Timothy S. Luongo, PhD, MSTR
Operator at Spark Therapeutics (Roche) and StrideBio, then buy-side evaluation at Sarepta Therapeutics. More about Tim →
Two examples
Anonymized, but the work and the numbers are real.
Preclinical Strategy
Gene Therapy, Rare Kidney Disease
Promising discovery data, no plan to get to the clinic. The roadmap that came out of the engagement cut 14 months off the projected timeline and is now executing.
Read the full case studyPortfolio Strategy
RNA Therapeutics Platform, 30+ Indications
An RNA platform with 30-plus possible indications and no way to choose. A scoring framework narrowed the field to three and became the team's standing decision tool.
Read the full case studyWhat Clients and Colleagues Say
“In my time working with Tim at Spark Therapeutics, he stood out for his ability to quickly identify what mattered most to reduce risk and keep teams focused on the highest-impact work. He translates complex data into clear priorities, crisp recommendations, and actionable next steps. He's highly collaborative and raises the quality of decision-making across functions. I would strongly recommend BridgeLine to any biotech building toward a key inflection point.”
Christopher Rilling, PhD
VP of Science, Parallel Bio
Frequently Asked Questions
How engagements work, what BridgeLine delivers, and what to expect
The BridgeLine Brief
Strategy breakdowns, deal analysis, and drug development insights you won't find anywhere else. Written from inside the industry by someone who has built programs and evaluated companies firsthand. Plus updates when we publish new guides, tools, and resources for early-stage biotech teams.
By subscribing you agree to our Privacy Policy.
Walk through your program
A direct conversation with the founder. Confidential. No deck required.
Get in touchConfidential · Response within one business day
info@bridgelinetranslational.com · bridgelinetranslational.com